"Philips Halts Sales of CPAP Machines in US Due to Safety Concerns"
TL;DR Summary
Philips has agreed to halt sales of its sleep apnea devices in the US due to safety concerns related to potential cancer risks from foam used in the devices. The company will continue servicing existing machines and has set aside $393 million for a settlement, pending court approval. The FDA had ordered Philips to improve outreach about the recall and be more transparent about the health risks. CEO Roy Jakobs emphasized the company's commitment to patient safety and quality.
- Philips to halt sales of sleep apnea machines in US over ongoing safety concerns USA TODAY
- Philips Suspends Sales of CPAP and Other Breathing Devices After Recall The New York Times
- Philips announces its 2023 Fourth-Quarter and Annual Results Philips
- Philips halts U.S. sales of CPAP breathing machines after recall The Washington Post
- Philips to halt CPAP sales in the U.S. as it takes $393 million provision MarketWatch
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
2 min
vs 3 min read
Condensed
83%
466 → 79 words
Want the full story? Read the original article
Read on USA TODAY